HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-8.31%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$972M
AUM Growth
+$972M
(-33%)
Cap. Flow
-$367M
Cap. Flow
% of AUM
-37.78%
Top 10 Holdings %
Top 10 Hldgs %
50.21%
Holding
77
New
12
Increased
11
Reduced
25
Closed
20
Top Buys
| 1 |
Hologic
HOLX
|
$27.9M |
| 2 |
Cigna
CI
|
$25.4M |
| 3 |
Eli Lilly
LLY
|
$22.9M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$18.2M |
| 5 |
Agilent Technologies
A
|
$16.4M |
Top Sells
| 1 |
Envista
NVST
|
$44.5M |
| 2 |
AbbVie
ABBV
|
$41.2M |
| 3 |
Teleflex
TFX
|
$35.2M |
| 4 |
Abbott
ABT
|
$31M |
| 5 |
CVS Health
CVS
|
$29M |
Sector Composition
| 1 | Healthcare | 96.07% |
| 2 | Consumer Discretionary | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Agilent Technologies
A
$35.6B
| $16.4M | 1.65% |
+138,280
| New | +$16.4M |
|
27
Intuitive Surgical
ISRG
$168B
| $14.5M | 1.46% |
+72,490
| New | +$14.5M |
|
28
Becton Dickinson
BDX
$53.9B
| $13.7M | 1.38% |
55,710
-85,750
| -61% | -$21.1M |
|
29
Universal Health Services
UHS
$11.6B
| $13.5M | 1.36% |
134,040
-94,370
| -41% | -$9.5M |
|
30
McKesson
MCK
$86B
| $11.4M | 1.15% |
35,040
-60,760
| -63% | -$19.8M |
|
31
Kezar Life Sciences
KZR
$28M
| $10M | 1.01% |
+1,209,880
| New | +$10M |
|
32
Cooper Companies
COO
$13B
| $9.64M | 0.97% |
30,770
-77,820
| -72% | -$24.4M |
|
33
Zimmer Biomet
ZBH
$20.8B
| $7.57M | 0.76% |
+72,020
| New | +$7.57M |
|
34
iShares Biotechnology ETF
IBB
$5.69B
| $6.35M | 0.64% |
53,940
+25,720
| +91% | +$3.03M |
|
35
Hyperfine
HYPR
$95.1M
| $6.13M | 0.62% |
2,749,400
+999,400
| +57% | +$2.23M |
|
36
DexCom
DXCM
$29.1B
| $5.57M | 0.56% |
+74,780
| New | +$5.57M |
|
|
AFMD
37
DELISTED
Affimed
AFMD
| $4.77M | 0.48% |
1,721,925
| – | – |
|
38
Health Care Select Sector SPDR Fund
XLV
$33.9B
| $4.44M | 0.45% |
+34,610
| New | +$4.44M |
|
39
RAPT Therapeutics
RAPT
$196M
| $3.96M | 0.4% |
217,165
-46,985
| -18% | -$857K |
|
40
Teva Pharmaceuticals
TEVA
$21.5B
| $3.76M | 0.38% |
+499,640
| New | +$3.76M |
|
41
Quanterix
QTRX
$209M
| $3.26M | 0.33% |
201,560
-44,980
| -18% | -$728K |
|
42
Galapagos
GLPG
$2.05B
| $3.09M | 0.31% |
55,280
+31,540
| +133% | +$1.76M |
|
43
Merus
MRUS
$5.01B
| $2.7M | 0.27% |
119,200
+7,440
| +7% | +$168K |
|
44
BioCryst Pharmaceuticals
BCRX
$1.74B
| $2.54M | 0.25% |
239,820
+11,370
| +5% | +$120K |
|
|
IMGN
45
DELISTED
Immunogen Inc
IMGN
| $2.25M | 0.23% |
500,000
-810,340
| -62% | -$3.65M |
|
46
Insulet
PODD
$24.3B
| $1.56M | 0.16% |
+7,150
| New | +$1.56M |
|
47
Geron
GERN
$938M
| $1.55M | 0.16% |
1,000,000
+100,000
| +11% | +$155K |
|
|
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.55M | 0.16% |
27,070
+13,500
| +99% | +$771K |
|
49
Leap Therapeutics
LPTX
$12.2M
| $1.23M | 0.12% |
1,066,689
| – | – |
|
|
IMA
50
ImageneBio, Inc. Common Stock
IMA
$149M
| $975K | 0.1% |
220,082
-67,539
| -23% | -$299K |
|